Oruka Therapeutics, Inc. (ORKA)
94.36
+0.81
(+0.87%)
USD |
NASDAQ |
Sep 17, 11:29
Oruka Therapeutics Enterprise Value : 4.845B for Sept. 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 16, 2026 | 4.845B |
| September 15, 2026 | 4.763B |
| September 14, 2026 | 4.990B |
| September 11, 2026 | 4.774B |
| September 10, 2026 | 4.729B |
| September 09, 2026 | 4.720B |
| September 08, 2026 | 4.891B |
| September 04, 2026 | 4.781B |
| September 03, 2026 | 4.689B |
| September 02, 2026 | 4.728B |
| September 01, 2026 | 4.757B |
| August 31, 2026 | 4.788B |
| August 28, 2026 | 4.698B |
| August 27, 2026 | 5.028B |
| August 26, 2026 | 5.205B |
| August 25, 2026 | 5.350B |
| August 24, 2026 | 5.387B |
| August 21, 2026 | 5.725B |
| August 20, 2026 | 5.536B |
| August 19, 2026 | 5.831B |
| August 18, 2026 | 6.038B |
| August 17, 2026 | 6.012B |
| August 14, 2026 | 5.913B |
| August 13, 2026 | 5.735B |
| August 12, 2026 | 5.691B |
| Date | Value |
|---|---|
| August 11, 2026 | 5.524B |
| August 10, 2026 | 5.553B |
| August 07, 2026 | 5.167B |
| August 06, 2026 | 5.142B |
| August 05, 2026 | 5.067B |
| August 04, 2026 | 5.125B |
| August 03, 2026 | 4.921B |
| July 31, 2026 | 5.026B |
| July 30, 2026 | 5.108B |
| July 29, 2026 | 4.510B |
| July 28, 2026 | 4.656B |
| July 27, 2026 | 4.640B |
| July 24, 2026 | 4.760B |
| July 23, 2026 | 4.747B |
| July 22, 2026 | 4.783B |
| July 21, 2026 | 4.892B |
| July 20, 2026 | 4.733B |
| July 17, 2026 | 4.793B |
| July 16, 2026 | 4.203B |
| July 15, 2026 | 4.424B |
| July 14, 2026 | 4.474B |
| July 13, 2026 | 4.296B |
| July 10, 2026 | 4.432B |
| July 09, 2026 | 4.523B |
| July 08, 2026 | 4.286B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -59.83M |
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 6.760M |
| Century Therapeutics, Inc. | 254.77M |
| Absci Corp. | 1.182B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.21M |
| Total Expenses (Quarterly) | 41.21M |
| EPS Diluted (Quarterly) | -0.6554 |
| Earnings Yield | -2.61% |
| Normalized Earnings Yield | -2.610 |